While reading ahead in our textbook, many of the immune therapies impressed me with their clinical applications. However, one in particular stood out to me. Chimeric Antigen Receptor T Cell Therapy (CAR T), discussed in chapter 17.3 of our textbook, is a form of T cell tranfer therapy in which cells are removed from the patients body and augmented with a receptor for a specific kind of cancer, according to The American Cancer Society. This therapy is still relatively new, and research is being constantly conducted concerning its potential applications (NIH National Cancer Institute). Currently, it is only used to treat leukemia, lymphoma, and multiple myeloma (The American Cancer Society).
To dive further in depth on the actual treatment process, one must understand how the aforementioned cancers function. Leukemia and Lymphoma are both cancers that target the blood and the lymphatic system, respectively (NIH National Cancer Institute). As a result, they are able to spread throughout the body rapidly, and treating the disease can be hard to do without killing things like healthy red blood cells. CAR T therapy is invaluable in this respect. Blood is harvested from the patient, their white blood cells are extracted from the sample, and then the rest of the blood is returned (The American Cancer Society). The T cells are then grown in a laboratory where they are fitted with an antigen-specific receptor that correlates to a certain kind of cancer such as Hodgkin’s Lymphoma (The American Cancer Society).
The patient is then treated with a low-dose of chemotherapy to suppress immune function (The American Cancer Society). The augmented T cells are reintroduced, where they then kill cancerous cells by latching on to the antigen presented on the surface of the malignant cell (The American Cancer Society). Just as a key fits into a lock, so does the cancerous antigen fit into the antigen-specific receptor on the augmented T cell. Currently, research is being conducted on the effectiveness of CAR T cell therapy against solid tumors such as ovarian cancer (Medscape). According to Medscape, CAR T cell therapy is being combined with an mRNA vaccine and is delivered intravenously. These therapies, while still in early stages, are showing promising results that suggest they may be able to be employed in the coming years (Medscape).










